Affordable Access

Publisher Website

Abacavir (Ziagen®) use between 2003 and 2008 in France according to the electronic medical record NADIS®

Médecine et Maladies Infectieuses
DOI: 10.1016/j.medmal.2013.09.012
  • Abacavir
  • Hiv
  • Dat’Aids
  • Vih
  • Biology
  • Medicine


Summary Objective The authors had for objective to describe HIV-infected patients treated with ABC (Ziagen®, ABC), and the immune, virological, and clinical treatment outcome between 2003 and 2008. Patients and methods We performed a retrospective analysis of the Dat’AIDS database on patients who were treated with ABC for the first time between 2003 and 2008. Results Eight hundred and thirty-six patients were included. Before initiation of ABC, 26.3% has stopped the previous treatment because of immuno-virological failure, 30.5% because of adverse events, and 29.8% for other reasons. Thirteen percent were antiretroviral naive. One third of patients were ranked as CDC class C, and more than 2/3 had a viral load<5 log copies/mL or a CD4 count≥200mm3. ABC was mainly included in a combination containing 2 NRTI and 1 PI (63%), or 1 non-NRTI (16%). Thirty-two percent of patients were still treated with ABC after 2years of treatment and the median of ABC treatment was 11months (IQ 84days–2years). The main causes for stopping ABC were therapeutic simplification (47.4% of patients), intolerance (19.0%), and immuno-virological failure (9.8%). Suspected hypersensitivity reactions were the main cause of discontinuation due to intolerance (27.6%); the rate was 3.8% when ABC had been introduced before the routine use of the screening test HLA-B*5701. The incidence of myocardial infarction was 3.8 per 1000 patient-years; 70.6% of patients received a fixed combination including ABC after discontinuation of ABC as a single agent (Ziagen®). Conclusion This retrospective analysis confirmed the effectiveness and the good tolerance of ABC in the therapeutic strategy, between 2003 and 2008.

There are no comments yet on this publication. Be the first to share your thoughts.